Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Cyclerion Therapeutics Inc (CYCN)

Cyclerion Therapeutics Inc (CYCN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Cyclerion Therapeutics Inc 245 FIRST STREET 18TH FLOOR CAMBRIDGE MA 02142 USA

www.cyclerion.com P: 857-327-8778 F: 617-890-6595

Description:

Cyclerion Therapeutics Inc. is a clinical-stage biopharmaceutical company harnessing the power of sGC pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. The company's product pipeline consists of Olinciguat, Praliciguat and IW-6463 which are in clinical stage. Cyclerion Therapeutics Inc. is based in Cambridge, United States.

Key Statistics

Overview:

Market Capitalization, $K 7,670
Enterprise Value, $K 100
Shares Outstanding, K 2,710
Annual Sales, $ 0 K
Annual Net Income, $ -5,260 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -1,690 K
EBIT, $ -12,950 K
EBITDA, $ -12,880 K
60-Month Beta 1.84
% of Insider Shareholders 13.10%
% of Institutional Shareholders 75.62%
Float, K 2,355
% Float 86.90%
Short Volume Ratio 0.87

Growth:

1-Year Return -48.73%
3-Year Return -94.87%
5-Year Return -99.15%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.93 on 11/13/23
Latest Earnings Date 05/09/24
Earnings Per Share ttm -5.96
EPS Growth vs. Prev Qtr 49.18%
EPS Growth vs. Prev Year 80.62%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-20 on 05/16/23

CYCN Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -111.79%
Return-on-Assets % -74.10%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 0.66
Book Value/Share 4.61
Interest Coverage -0.10
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar